NKGen Biotech CEO to present troculeucel Alzheimer’s data at 2026 BIOCHINA Global Forum

NKGen Biotech, Inc.

NKGen Biotech, Inc.

NKGN

0.00
  • NKGen Biotech flagged a potential strategic push for troculeucel in neurodegenerative disease at the 2026 BIOCHINA Global Forum on July 10.
  • Management will outline Phase 2 Alzheimer’s trial status for the autologous NK-cell therapy, signaling a broader development and partnering narrative.
  • Presentation includes discussion of China regulatory pathways in select free-trade zones that could support development or commercialization of Phase 2-stage assets.
  • Company expects post-conference release of presentation materials on its website.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nkgen Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607020805PRIMZONEFULLFEED9752280) on July 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.